Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITIS-TNK2: Repeated Intravenous Thrombolysis for Ischemic Stroke With Tenecteplase
NCT07375966Phase 2Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Rate of vessel recanalization at 24 hours. Started Mar 2026; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07375966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07375966.